ID   TMD8
AC   CVCL_A442
SY   TMD-8; Tokyo Medical and Dental university 8
DR   EFO; EFO_0006496
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-4956
DR   Cosmic; 1486587
DR   Cosmic; 1945194
DR   Cosmic; 2129635
DR   GEO; GSM1059801
DR   GEO; GSM1374963
DR   GEO; GSM1527304
DR   GEO; GSM1527305
DR   GEO; GSM1527306
DR   GEO; GSM1527307
DR   GEO; GSM1527308
DR   GEO; GSM1527309
DR   GEO; GSM1890021
DR   GEO; GSM1890022
DR   GEO; GSM1890023
DR   GEO; GSM1890024
DR   GEO; GSM2037048
DR   GEO; GSM2037049
DR   PharmacoDB; TMD8_1600_2019
DR   Progenetix; CVCL_A442
DR   Wikidata; Q54972694
RX   PubMed=16780947;
RX   PubMed=23292937;
RX   PubMed=25485619;
RX   PubMed=27566572;
RX   PubMed=29416618;
RX   PubMed=29666304;
CC   Population: Japanese.
CC   Characteristics: Genetic heterogeneous, consists of 3 subclones (PubMed=27566572).
CC   Doubling time: ~30 hours (PubMed=16780947).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Misspelling: TDM8; In PubMed=23292937.
CC   Derived from sampling site: Bone marrow.
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-10-20; Version: 23
//
RX   PubMed=16780947; DOI=10.1016/j.leukres.2006.05.003;
RA   Tohda S., Sato T., Kogoshi H., Fu L., Sakano S., Nara N.;
RT   "Establishment of a novel B-cell lymphoma cell line with suppressed
RT   growth by gamma-secretase inhibitors.";
RL   Leuk. Res. 30:1385-1390(2006).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S., Medeiros L.J., Ford R.J.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//